Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Condition(s):Plague, Pneumonic; Plague; Vaccine-Preventable DiseasesLast Updated:February 28, 2024Active, not recruiting